Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Benjamin J. Zeskind
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 57
- Beta
- 0.39
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 5.15
Financials
Revenue
$0.00-100.0%Net Income
$-17.27MEBITDA
$-17.18MFree Cash Flow
$-16.53MEPS (diluted)
$-0.27Shares Outstanding (diluted)
64.70M+378.8%Operating Expenses
$18.99MCash & Debt
$149.90MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-56.02M | $-1.27 |
| 2024 | $0.00 | $-61.04M | $-2.04 |
| 2023 | $0.00 | $-53.47M | $-1.88 |
| 2022 | $317.0K | $-50.51M | $-1.87 |
| 2021 | $2.08M | $-33.54M | $-1.27 |
| 2020 | $2.31M | $-17.04M | $-1.26 |
| 2019 | $1.92M | $-7.71M | $-0.60 |
Valuation
IMRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·12d ago·Negative
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer - Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study -
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
Immuneering to Present at the ESMO Congress 2026 NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a trial in progress abstract featuring the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) for the treatment of first-line pancreatic cancer (NCT07562152) has been accepted …
View source ↗ - Newsglobenewswire.com·30d ago·Negative
… overall survival implications of both preserving body mass and reducing tumor volume - NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development taking place September 25-28, 2026, in S…
View source ↗ - Newsglobenewswire.com·37d ago·Neutral
Immuneering to Participate in Upcoming Investor Conferences NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management plans to participate in the following upcoming investor conferences: Cantor Global Healthcare Conference (September 9-11 in New York City) Format: Fireside Chat and 1x1 Investor Meetings Date/Time: Thursday, September …
View source ↗ - Newsglobenewswire.com·45d ago·Negative
…in ≥10% of patients were anemia (16%) and neutropenia (18%), both chemotherapy-related - NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today shared comments following the recent FDA approval of a new second-line pancreatic cancer treatment. “Approval of this new treatment is good news for the subset of pancreatic cancer patients who have received at least…
View source ↗
Earnings
Wed, Nov 11(in 4 weeks)
Consensus estimate $-0.29 per share
Typical surprise -2.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.27 vs $-0.26miss
- Fri, May 15$-0.21 vs $-0.30beat
- Fri, Mar 6$-0.18 vs $-0.31beat
- Wed, Nov 12$-0.38 vs $-0.37miss
- Wed, Aug 13$-0.40 vs $-0.40beat
- Mon, May 5$-0.42 vs $-0.41miss
Estimates and results for IMRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IMRX officers and directors.
- Bought
- $757k
- Sold
- —
25 trades
0 trades
- Zeskind Benjamin J.bought
- Hall Brett Matthewbought
- Brakewood Harold Eugenebought
- Schall Thomas J.bought
- Hall Brett Matthewbought
- Neufeld Leah Rbought
- Feinberg Peterbought
- Feinberg Peterbought
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.